In terms of the novel combination therapies, Wang et al. found that in AXL-low expressing EGFR-mutated lung cancer, osimertinib resistance was driven by insulin-like growth factor-1 receptor (IGF-1R) expression and phosphorylation. The gene discussed is EGFR; the disease is lung cancer.